.png)
Cnoga Medical
Non-invasive glucometer and 16-parameter blood/vitals monitor (TensorTip); needle-free remote monitoring
Latest event found: 5 Mar 2025 · over 1 year ago · nothing in the last 12 months
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
Cnoga Medical appears focused on commercializing noninvasive, multispectral optical monitoring through glucometer, biomarker, vital-sign, and remote-care products. Public evidence indicates international market development and clinical positioning, but limited recent dated evidence of acceleration, regulatory progress, or major customer wins.
Efficiency Ratio
The company shows a relatively broad product and geographic ambition for a 51-200-person organization, suggesting potentially strong resource-to-output efficiency, although limited public operating data prevents firm validation.
Evidence Signals
Background · older than 12 months
Cnoga promoted the TensorTip Combo Glucometer, combining invasive and noninvasive glucose measurement, with CE approval and FDA submission pending.
BOE agreed through a wholly owned subsidiary to invest $50 million for approximately 23.81% of Cnoga through newly issued shares.
The investment included joint marketing of Cnoga products in China and development of a new professional-health product line.
- About
- Israeli medical-device company (Cnoga Medical Ltd.; HQ Caesarea, Israel; founded 2004; founder Dr. Yosef Segman; ~51-200 staff; privately held, $70M+ invested) developing non-invasive, pain-free optical blood-monitoring devices and telemedicine. Its TensorTip family includes the Combo Glucometer (CoG) for needle-free glucose measurement and the TensorTip MTX/VSM, which measures ~16 blood/vital bio-parameters non-invasively in under a minute — cuffless blood pressure, hemoglobin, hematocrit, RBC, pulse, SpO2, pH, blood gases and hemodynamics (cardiac output, stroke volume, MAP) — plus a forthcoming 'Smart Capsule' wearable glucometer/biomarker sensor, all with mobile/web/cloud connectivity for remote patient monitoring. Devices are CE-certified as Class 2a (since May 2014) and ISO 13485 registered, with FDA marketing clearance for the blood-pressure/pulse (PPM) device; commercialized across Europe, Asia and South America (deployments incl. community clinics in Brazil and remote-monitoring projects in Puglia, Italy). Defense relevance: non-invasive continuous vitals/biomarker monitoring fits the casualty-monitoring cluster (peer to Biobeat/Neteera/CardiacSense), but Cnoga is civilian-first (diabetes/chronic-disease, home & rural telemedicine) with no defense credential.
- Tags
- #noninvasive #glucometer #biomarkers #vitalsigns #wearable #monitoring #ce #device #dualuse